SummaryAvalere experts examined the changing oncology landscape amid the COVID-19 pandemic.
The oncology landscape continues to evolve, with delays to preventative screenings and care during the COVID-19 pandemic and an influx of approved immunotherapy and other targeted therapy products. Stakeholders will be impacted by a changing payer mix with growth in managed markets, continued investment in diagnosis and treatment options, and a focus on value. Join us for a discussion on these shifts and what to expect going forward.
- Impact of COVID-19 on access and health equity, including insurance coverage shifts, changes in reimbursement, and telehealth adoption
- Areas of innovation and market growth, including advances in diagnosis and treatment
- Strategies to demonstrate value, especially for targeted therapies